{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117504","form_type":"8-K/A","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.278745+00:00","generated_at":"2026-06-21T20:13:41.385871+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Theravance Biopharma completes sale of TRC units to Royalty Pharma for $1.107 billion cash","bullets":["Sold 2,125 Class B and 6,375 Class C units of Theravance Respiratory Company to Royalty Pharma on July 20, 2022.","Total cash consideration of $1.107 billion, net of $420 million payoff of 9.5% non-recourse notes due 2035.","Pro forma net gain of approximately $931.8 million recorded, with estimated income tax payable of $120.6 million.","Pro forma financials show elimination of $148.3 million equity investment and $396.1 million non-recourse notes.","Transaction qualifies as discontinued operations; pro forma net loss of $68.1 million for six months ended June 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117504","json":"https://secwatch.observer/filing/0001104659-22-117504.json","markdown":"https://secwatch.observer/filing/0001104659-22-117504.md","text":"https://secwatch.observer/filing/0001104659-22-117504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922117504/0001104659-22-117504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922117504/tm2229804d4_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:13:41.385871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}